Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDDIS-IDDS Validation with 99mTc-DTPA
NCT07053696Phase 1Withdrawn
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial. Primary endpoints: Segmental lung deposition of 99mTc-DTPA at 30 minutes and Incidence of treatment-emergent adverse events at 24 hours. Planned start Mar 2025; status: withdrawn.
Beyond the preview
Go deeper on NCT07053696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053696.